NASDAQ:CCCC C4 Therapeutics (CCCC) Stock Price, News & Analysis $2.12 +0.07 (+3.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.16 +0.04 (+1.89%) As of 08/1/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About C4 Therapeutics Stock (NASDAQ:CCCC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get C4 Therapeutics alerts:Sign Up Key Stats Today's Range$1.99▼$2.1950-Day Range$1.24▼$2.4252-Week Range$1.09▼$7.22Volume750,601 shsAverage Volume1.53 million shsMarket Capitalization$150.54 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company Overview C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Read More C4 Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCCCC MarketRank™: C4 Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 552nd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingC4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageC4 Therapeutics has received no research coverage in the past 90 days.Read more about C4 Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.52) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of C4 Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of C4 Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioC4 Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about C4 Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.73% of the outstanding shares of C4 Therapeutics have been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in C4 Therapeutics has recently decreased by 17.94%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldC4 Therapeutics does not currently pay a dividend.Dividend GrowthC4 Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.73% of the outstanding shares of C4 Therapeutics have been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in C4 Therapeutics has recently decreased by 17.94%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for C4 Therapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for CCCC on MarketBeat in the last 30 days. MarketBeat Follows1 people have added C4 Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, C4 Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.73% of the stock of C4 Therapeutics is held by insiders.Percentage Held by Institutions78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about C4 Therapeutics' insider trading history. Receive CCCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CCCC Stock News HeadlinesC4 Therapeutics: An Entry Point If There's Ever Going To Be OneJune 16, 2025 | seekingalpha.comC4 Therapeutics reports Q1 EPS (37c), consensus (42c)May 7, 2025 | msn.comOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.August 2 at 2:00 AM | InvestorPlace (Ad)C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 7, 2025 | finanznachrichten.deC4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 7, 2025 | globenewswire.comC4 Therapeutics Inc. CCCC (U.S.: Nasdaq)May 1, 2025 | wsj.comC4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk HereMarch 10, 2025 | seekingalpha.comC4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 1, 2025 | finanznachrichten.deSee More Headlines CCCC Stock Analysis - Frequently Asked Questions How have CCCC shares performed this year? C4 Therapeutics' stock was trading at $3.60 at the beginning of 2025. Since then, CCCC shares have decreased by 41.1% and is now trading at $2.12. How were C4 Therapeutics' earnings last quarter? C4 Therapeutics, Inc. (NASDAQ:CCCC) released its earnings results on Wednesday, May, 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.11. The company had revenue of $7.20 million for the quarter, compared to the consensus estimate of $3.54 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 45.86% and a negative net margin of 259.60%. When did C4 Therapeutics IPO? C4 Therapeutics (CCCC) raised $150 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO. Who are C4 Therapeutics' major shareholders? Top institutional investors of C4 Therapeutics include Y Intercept Hong Kong Ltd (0.07%), R Squared Ltd (0.04%) and Brookstone Capital Management (0.04%). View institutional ownership trends. How do I buy shares of C4 Therapeutics? Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of C4 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that C4 Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/07/2025Today8/02/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CCCC CIK1662579 Webwww.c4therapeutics.com Phone617-231-0700FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Price Target for C4 Therapeutics$12.00 High Price Target$20.00 Low Price Target$4.00 Potential Upside/Downside+466.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.32 million Net Margins-259.60% Pretax Margin-259.27% Return on Equity-45.86% Return on Assets-28.96% Debt Debt-to-Equity RatioN/A Current Ratio5.70 Quick Ratio5.70 Sales & Book Value Annual Sales$35.58 million Price / Sales4.23 Cash FlowN/A Price / Cash FlowN/A Book Value$3.06 per share Price / Book0.69Miscellaneous Outstanding Shares71,010,000Free Float64,808,000Market Cap$150.54 million OptionableOptionable Beta2.97 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CCCC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.